Valeant Pharmaceuticals Under Fresh Scrutiny Over Drug PricingMani
Valeant Pharmaceuticals disclosed late Wednesday that it was subpoenaed by U.S. prosecutors seeking information on its pricing programs.
In early trading on Thursday, Valeant’s U.S.-listed shares were down 9% at $156.53.
Valeant under fire for increasing drug prices
Valeant Pharmaceuticals has received subpoenas from U.S. prosecutors seeking information on drug-pricing decisions. In a statement on Wednesday night, the . . .
This content is exclusively for paying members.
If you are subscribed and having an account error please clear cache and cookies if that does not work email [email protected] or click Chat.